# Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

> **NCT05698147** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tong Chen, MD** · enrollment: 30 (estimated)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Rituximab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT05698147
- **Lead sponsor:** Tong Chen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698147, "Selinexor in Combination With MTX+Ritu to Treat R/R CNSL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05698147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*